Risk of Alzheimer''s Disease among Type 2 Diabetic Patients Receiving Metformin

碩士 === 中山醫學大學 === 醫學研究所 === 103 === Objective:Several studies have shown that diabetes is associated with Alzheimer''s diseasebut with conflicting results inrecent years. Therefore , we aim to investigate whether using oral hypoglycemic agentmetformin in type 2 diabetic patients increases...

Full description

Bibliographic Details
Main Authors: Hui-Wen Hsiao, 蕭惠文
Other Authors: Chih-Li Lin
Format: Others
Language:zh-TW
Published: 2015
Online Access:http://ndltd.ncl.edu.tw/handle/63833889987167295181
id ndltd-TW-103CSMU5534014
record_format oai_dc
spelling ndltd-TW-103CSMU55340142016-10-23T04:13:04Z http://ndltd.ncl.edu.tw/handle/63833889987167295181 Risk of Alzheimer''s Disease among Type 2 Diabetic Patients Receiving Metformin 第二型糖尿病病患使用Metformin藥物與阿茲海默症之風險探討 Hui-Wen Hsiao 蕭惠文 碩士 中山醫學大學 醫學研究所 103 Objective:Several studies have shown that diabetes is associated with Alzheimer''s diseasebut with conflicting results inrecent years. Therefore , we aim to investigate whether using oral hypoglycemic agentmetformin in type 2 diabetic patients increases the risk of developing Alzheimer''s disease. Materials andMethods:This is a retrospective case-control study. Froma databank of Longitudinal Cohort of Diabetes Patients(LHDB)retrieved from national health insurance in Taiwan, we obtained 66,293 type 2 diabetic patients treated with oral hypoglycemic agents during 1999-2011. Risk-set sampling was used to define patients suffering from Alzheimer''s disease, while propensity score was performedfor case pairing with control groups. Conditional logistic regression was used to analyzethe risk of developing Alzheimer''s disease in type 2 diabetic patients treated withMetformin. Results:There were 872 patients diagnosed with Alzheimer''s diseaseduring this cohort. Among these patients,79.1%(n=690) were treated with metformin,while in the control group (n=3488),74.7% (n=2607) were treated with metformin. Overall, the result shows statistically significant association between metforminuse and the development of Alzheimer''s disease〔adjusted OR 1.28(95% CI 1.03-1.59)〕. Interestingly, diabetes patients with current use, low cumulative dose(≦1000 mg), low daily dose(≦0.5 DDD/day), and short duration(≦3 years)had significantly higher risk of developing Alzheimer''s disease[adjusted OR(95% CI)of current use;low cumulative dose;low daily dose;short duration:2.88(2.20-3.79);1.29(1.01-1.65);1.39(1.11-1.74);1.27(1.02-1.58), respectively.] Conclusion:Among diabetes patients older than 65 years of age,increased risk of Alzheimer''s disease under current using metformin was proved. Furthermore, low dose and short duration use of metformin also have higher risk in developing Alzheimer''s disease. Chih-Li Lin Chien-Ning Huang 林志立 黃建寧 2015 學位論文 ; thesis 62 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 中山醫學大學 === 醫學研究所 === 103 === Objective:Several studies have shown that diabetes is associated with Alzheimer''s diseasebut with conflicting results inrecent years. Therefore , we aim to investigate whether using oral hypoglycemic agentmetformin in type 2 diabetic patients increases the risk of developing Alzheimer''s disease. Materials andMethods:This is a retrospective case-control study. Froma databank of Longitudinal Cohort of Diabetes Patients(LHDB)retrieved from national health insurance in Taiwan, we obtained 66,293 type 2 diabetic patients treated with oral hypoglycemic agents during 1999-2011. Risk-set sampling was used to define patients suffering from Alzheimer''s disease, while propensity score was performedfor case pairing with control groups. Conditional logistic regression was used to analyzethe risk of developing Alzheimer''s disease in type 2 diabetic patients treated withMetformin. Results:There were 872 patients diagnosed with Alzheimer''s diseaseduring this cohort. Among these patients,79.1%(n=690) were treated with metformin,while in the control group (n=3488),74.7% (n=2607) were treated with metformin. Overall, the result shows statistically significant association between metforminuse and the development of Alzheimer''s disease〔adjusted OR 1.28(95% CI 1.03-1.59)〕. Interestingly, diabetes patients with current use, low cumulative dose(≦1000 mg), low daily dose(≦0.5 DDD/day), and short duration(≦3 years)had significantly higher risk of developing Alzheimer''s disease[adjusted OR(95% CI)of current use;low cumulative dose;low daily dose;short duration:2.88(2.20-3.79);1.29(1.01-1.65);1.39(1.11-1.74);1.27(1.02-1.58), respectively.] Conclusion:Among diabetes patients older than 65 years of age,increased risk of Alzheimer''s disease under current using metformin was proved. Furthermore, low dose and short duration use of metformin also have higher risk in developing Alzheimer''s disease.
author2 Chih-Li Lin
author_facet Chih-Li Lin
Hui-Wen Hsiao
蕭惠文
author Hui-Wen Hsiao
蕭惠文
spellingShingle Hui-Wen Hsiao
蕭惠文
Risk of Alzheimer''s Disease among Type 2 Diabetic Patients Receiving Metformin
author_sort Hui-Wen Hsiao
title Risk of Alzheimer''s Disease among Type 2 Diabetic Patients Receiving Metformin
title_short Risk of Alzheimer''s Disease among Type 2 Diabetic Patients Receiving Metformin
title_full Risk of Alzheimer''s Disease among Type 2 Diabetic Patients Receiving Metformin
title_fullStr Risk of Alzheimer''s Disease among Type 2 Diabetic Patients Receiving Metformin
title_full_unstemmed Risk of Alzheimer''s Disease among Type 2 Diabetic Patients Receiving Metformin
title_sort risk of alzheimer''s disease among type 2 diabetic patients receiving metformin
publishDate 2015
url http://ndltd.ncl.edu.tw/handle/63833889987167295181
work_keys_str_mv AT huiwenhsiao riskofalzheimersdiseaseamongtype2diabeticpatientsreceivingmetformin
AT xiāohuìwén riskofalzheimersdiseaseamongtype2diabeticpatientsreceivingmetformin
AT huiwenhsiao dìèrxíngtángniàobìngbìnghuànshǐyòngmetforminyàowùyǔāzīhǎimòzhèngzhīfēngxiǎntàntǎo
AT xiāohuìwén dìèrxíngtángniàobìngbìnghuànshǐyòngmetforminyàowùyǔāzīhǎimòzhèngzhīfēngxiǎntàntǎo
_version_ 1718389639570522112